POLISH JOURNAL OF PATHOLOGY波兰病理学杂志
POLISH JOURNAL OF PATHOLOGY(英文缩写 POL J PATHOL),ISSN 1233-9687,eISSN 1233-9687,中文译名:波兰病理学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-10-01 至 2026-09-30，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 0.909 | Q4 |
| 2022 | 0.800 | Q4 |
| 2023 | 0.700 | Q4 |
| 2024 | 0.600 | Q4 |
| 2025 | 0.800 | Q4 |
POLISH JOURNAL OF PATHOLOGY 最新收录文献
-
1. The role of computational pathology in predicting expression of selected immunohistochemical markers.
PMID:日期:2026-06-25Immunohistochemistry (IHC) remains a cornerstone of precision oncology, providing essential diagnostic, prognostic, and predictive molecular data. However, the traditional manual assessment of IHC slides faces persistent challenges regarding interobserver variability, reproducibility, and high diagnostic workloads. To address these limitations, artificial intelligence (AI) is increasingly integrated into computational pathology workflows. This paper outlines the current landscape of AI-assisted IHC, highlighting significant trends such as automated scoring, explainable AI, virtual staining, and multiplex analysis. We explore the transition from basic image analysis to advanced deep learning architectures capable of predicting specific IHC biomarker expression directly from standard hematoxylin and eosin morphology. Furthermore, we examine the commercial ecosystem of these tools and highlight the critical pre-analytical bottlenecks that hinder widespread clinical adoption. Finally, we present a practical case study demonstrating an automated, deep learning- based pipeline for quantifying CD34-positive myeloblasts in acute myeloid leukemia and myelodysplastic syndromes. Ultimately, while AI holds vast potential to optimize turnaround times and streamline laboratory triage, its successful clinical implementation will depend on seamless integration into existing digital pathology platforms and standardization of pre-analytical variables, moving the field from fragmented algorithms to reliable, standard-of-care diagnostic tools.
-
2. Generation of virtual stains - can AI imitate chemistry?
PMID:日期:2026-06-25Histological staining is the foundation of anatomic pathology, yet traditional wet-lab workflows are slow, consume irreplaceable tissue, and are prone to artifactual variability. As precision oncology increasingly demands comprehensive molecular testing from limited biopsy samples, conserving tissue while delivering rapid, accurate diagnoses is an urgent clinical challenge. This review explores "virtual staining" - the digital generation of routine and special stains directly from label-free tissue scans or primary hematoxylin and eosin slides. We examine the shift toward advanced artificial intelligence models that preserve overall tissue architecture, the development of "pathology-aware" quality metrics, and clinical applications like instant multiplexed immunofluorescence and 3D intraoperative biopsies. Ultimately, virtual staining allows pathologists to simultaneously evaluate multiple diagnostic stains without depleting the physical block or waiting for laboratory processing. By adopting rigorous quality controls and optimizing for time-sensitive clinical workflows, this technology is poised to transition from a research novelty into a fundamental tool for preserving invaluable patient tissue and accelerating diagnostic turnaround times.
-
3. p16/Ki-67 dual-stain immunocytochemistry in precision cervical cancer prevention: immunoprofile and clinical decision-making.
PMID:日期:2026-06-25Cervical cancer prevention has undergone a major shift with the implementation of human papillomavirus (HPV)-based screening, which offers high sensitivity but limited specificity due to the detection of transient infections. This has created a need for triage methods capable of identifying infections associated with clinically meaningful disease. Primary HPV testing provides a high level of reassurance when negative; however, individuals with a positive result require additional evaluation using triage methods that effectively identify precancerous lesions while avoiding unnecessary colposcopy referrals. This review addresses the role of p16/Ki-67 dual-stain (DS) immunocytochemistry as a biomarker of transforming HPV infection, with a focus on HPV-based screening settings. We discuss its biological basis and diagnostic performance in comparison with cytology, with particular attention to the principles and practical aspects of DS interpretation in routine cytopathological practice. We also summarize current evidence, including data from national studies and routine clinical practice, demonstrating that DS can be effectively integrated into screening pathways and support more informed clinical decision-making. Its increasing use reflects the broader transition toward biologically informed cervical cancer prevention.
-
4. Immunohistochemistry in the differential diagnosis of cutaneous spindle cell neoplasms.
PMID:日期:2026-06-25Cutaneous spindle cell neoplasms may cause considerable problems in the diagnosis and proper treatment of affected patients. After exclusion of nonmesenchymal spindle cell lesions, including /spindle cell (sarcomatoid) carcinoma as well as spindle cell and desmoplastic melanoma, the line of differentiation and the dignity must be established. Immunohistochemical stainings are very important in this process, and a number of examples of cutaneous spindle cell neoplasms are described.
-
5. Pitfalls in the diagnosis of melanocytic tumours: is immunohistochemistry helpful?
PMID:日期:2026-06-25The diagnosis and differential diagnosis of benign, intermediate and malignant melanocytic neoplasms remain a recurring and clinically important challenge in dermatopathology. The difficulty is not limited to rare melanoma variants, it also includes non-melanocytic lesions that simulate melanocytic tumours, benign melanocytic proliferations with worrisome architectural or cytological features, and malignant melanomas with deceptively bland morphology. In such settings, immunohistochemistry is not a substitute for careful histopathological assessment, but it may provide decisive ancillary information when applied as a targeted panel and interpreted in the appropriate morphological and clinical context. This review summarises selected diagnostic pitfalls in melanocytic pathology and highlights the contribution, limitations and practical value of established and newer immunohistochemical markers.
-
6. New technologies in the genomic evaluation of lymphomas.
PMID:日期:2026-06-25Lymphomas represent a heterogenous group of lymphoid neoplasms with a broad spectrum of clinical presentations and challenges in therapy resistance and relapse. Response to treatment and prognosis vary between and within lymphoma subtypes. The introduction of high-throughput molecular profiling methods and next-generation sequencing technologies has significantly enhanced our understanding of lymphomagenesis and improved the description of the tumour subtypes at the molecular level. Still, the current diagnosis of lymphomas is mostly based on morphological evaluation and immunophenotyping. This article describes how newly developed molecular assays already complement clinical diagnoses and have an impact on disease classification. Also, their contribution to risk stratification, therapy prediction, and disease monitoring for certain categories of lymphomas is discussed.
-
7. Challenging cases of Epstein-Barr virus positive lymphomas.
PMID:日期:2026-06-25Epstein-Barr virus (EBV)-associated lymphomas can develop in both immuno- competent and immunocompromised patients, such as those with human immunodeficiency virus (HIV) infection, other primary or acquired immunodeficiencies, or post transplantation. The current World Health Organization classification consolidated immunodeficiency/dysregulation-related lymphoproliferative disorders into three major histopathological categories: hyperplasia, lymphoproliferative disorder of varied malignant potential, and lymphoma; and reporting the histopathological category, the presence or absence of causally associated viruses (EBV, KSHV/HHV-8), and the immune deficiency/dysregulation setting is recommended. In hematopathology practice, EBV is best confirmed by EBV-encoded RNA in situ hybridization, while immunohistochemistry is used as a complementary test for the presence of EBV-related proteins. Often, additional analyses such as fluorescence in situ hybridization and polymerase chain reaction for B- and T-cell clonality have to be applied for the final classification. This review, summarizing a lecture given at the 10th Course of the Academy of Immunohistochemistry in Cracow, Poland (June 2026), presents some challenging examples of EBV-related lymphomas. Cases include EBV+ mucocutaneous ulcer with subsequent EBV+ diffuse large B-cell lymphoma, EBV+ diffuse large B-cell lymphoma with plasma cell differentiation, post therapy EBV+ Burkitt lymphoma and cutaneous NK/T-cell lymphoma.
-
8. Immunohistochemical and molecular diagnostics tailoring personalised ovarian cancer therapy.
PMID:日期:2026-06-25Ovarian cancer remains the most lethal gynaecological malignancy, and it exhibits substantial histologic and molecular heterogeneity. Traditional systemic therapies have produced only modest survival gains. Integration of immunohistochemical (IHC) and molecular diagnostics has shifted care toward biomarker-driven personalised treatment. This review presents current IHC approaches for histotype classification and the most important actionable protein markers (FR, HER2, TROP2, MMR proteins, and PD-L1), together with molecular testing for BRCA1/2, homologous recombination deficiency (HRD) status, and circulating tumour DNA (ctDNA) monitoring. These diagnostics now direct poly(ADP-ribose) polymerase inhibitors maintenance in HRD-positive disease and antibody-drug conjugates such as mirvetuximab soravtansine in FR-high platinum-resistant tumours. However, important limitations remain: intratumoral heterogeneity, variable assay performance, lack of standardisation, and unequal access to testing worldwide. We also discuss how best to combine multiple biomarkers and outline future directions, such as AI-assisted digital pathology, composite predictive models, and ctDNA-guided adaptive strategies, to refine patient selection and improve long-term outcomes.
-
9. Immunohistochemistry in placental pathology.
PMID:日期:2026-06-25Although the clinical background, gross and hematoxylin-eosin examination usually suffice for the placental diagnosis, immunohistochemistry (IHC) is essential in many cases, particularly in high-risk pregnancy. The double E-cadherin/CD34 immuno-stain is the backbone of it, particularly for diagnosing the early fetal vascular malper-fusion (FVM) characterized by the endothelial fragmentation preceding the villous hypovascularity/avascularity of distal FVM. The stain is 3-4 times more sensitive than the stromal vascular karyorrhexis, the other early FVM lesion. The endothelial fragmentation may help in timing FVM and its grading as well as in revealing its temporal heterogeneity. The immunostain makes the FVM the most common pattern of placental injury in the population of pregnancies dominated by mass-forming fetal anomalies. The immunostain is also useful in diagnosing villous hypomaturity by highlighting widened vasculosyncytial membranes. Of other immunostains, cyto-keratin IHC is invaluable for confirmation of intrauterine pregnancy in chorionic villi-negative uterine curettings. Cytokeratin and smooth muscle actin are valuable in borderline cases of shallow placental implantation. P57 immunostain is invaluable for the diagnosis of early complete hydatidiform moles. Finally, IHC may be decisive in diagnosing viral placentitis, particularly cytomegaloviral, herpetic and parvoviral.
-
10. New and emerging entities of uterine mesenchymal tumours in the era of molecular testing.
PMID:日期:2026-06-25Uterine mesenchymal tumours represent a group of heterogeneous tumours, the classification of which is evolving, especially in the context of a broader use of molecular testing. Some entities can be diagnosed based on the combination of morphological and immunohistochemical features. In other entities, such as endometrial sarcomas with KAT6B/A::KANSL1 fusion, the correct diagnosis cannot currently be achieved without molecular testing. In this review, we focus on some of the new entities in which molecular testing plays an essential role for diagnosis, including tumours with KAT6B/A::KANSL1 fusion, tumours with MEIS1::NCOA2 fusion, and tumours with fusion involving the KDM2B gene. In addition, uterine tumours with whorling and GREB1:CTNNB1 fusion and endometrial stromal tumours with CTNNB1 mutation will be discussed. Other tumours with recurrent molecular alterations not specific to a single entity (such as tumours with PLAG1 fusion or RAD51B fusion) are also mentioned. In summary, molecular testing is a very important part of the classification of uterine mesenchymal tumours. The growing number of emerging entities helps to correctly classify tumours into clinically significant categories. However, these entities should be viewed with caution until their clinical significance is supported by robust data, and molecular findings should always be correlated with morphological features.